Abstract: Objective To investigate the efficacy and safety of synchronous intensity modulated radiation therapy （IMRT） combined with weekly dose of paclitaxel and cisplatin for locally advanced esophageal cancer. Methods From January 2010 to April 2015， 36 patients with previously untreated locally advanced esophageal cancer were assigned to receive weekly paclitaxel （50 mg／m2） and cisplatin （25 mg／m2） plus concurrent IMRT. The total radiation dose was 60 Gy in 30 fractions with 5 fractions a week. Response to radiochemotherapy was assessed by RECIST criteria 1.1 and toxicity was evaluated according to National Cancer Institute Common Toxicity Criteria 4.0. The clinical follow-up data from radiochemotherapy were investigated. Results All patients were available for evaluation. Seventeen got complete response， 13 cases had partial response， 4 cases had stable disease and 2 cases had progressive disease. The response rate was 83.3％ and the disease control rate was 94.4％. Of the 36 patients， the median progression-free survival was 13.0 months and median overall survival was 25.0 months. The 1-， 2-， 3-year survival rates were 77.8％， 63.9％ and 33.3％. Grade 3 or higher major toxicity consisted of leukopenia （25.0％），febrile neutropenia （11.1％）， anorexia （27.8％） and esophagitis （25.0％）. Conclusion The IMRT combined with weekly dose of paclitaxel and cisplatin is effective and tolerated in the treatment of locally advanced esophageal cancer.